卵巢癌与免疫系统。
Ovarian cancer and the immune system.
作者信息
Baert Thaïs, Vergote Ignace, Coosemans An
机构信息
Department of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Department of Oncology, Laboratory for Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.
Department of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Department of Oncology, Laboratory of Gynaecological Oncology, KU Leuven, Leuven, Belgium.
出版信息
Gynecol Oncol Rep. 2017 Jan 6;19:57-58. doi: 10.1016/j.gore.2017.01.002. eCollection 2017 Feb.
Abstract
Short communication in response to the review of Turner et al. entitled "Ovarian cancer and the immune system - the role of targeted therapies" published in Gynecological Oncology. We believe systemic immune parameters might be a good alternative to tumor biopsy to gain insight in the immunological background of ovarian cancer.
摘要
针对Turner等人发表在《妇科肿瘤学》上题为“卵巢癌与免疫系统——靶向治疗的作用”的综述的简短通讯。我们认为，全身免疫参数可能是一种很好的替代肿瘤活检的方法，有助于深入了解卵巢癌的免疫背景。
相似文献
1
Ovarian cancer and the immune system.
Gynecol Oncol Rep. 2017 Jan 6;19:57-58. doi: 10.1016/j.gore.2017.01.002. eCollection 2017 Feb.
2
Immunological parameters as a new lead in the diagnosis of ovarian cancer.
Facts Views Vis Obgyn. 2015;7(1):67-72.
3
Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors.
Int J Gynecol Cancer. 2019 Nov;29(9):1381-1388. doi: 10.1136/ijgc-2019-000521.
4
Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
Gynecol Oncol. 2010 May;117(2):366-72. doi: 10.1016/j.ygyno.2010.01.019. Epub 2010 Feb 9.
5
Myeloid-derived suppressor cells and their role in gynecological malignancies.
Tumour Biol. 2018 Jul;40(7):1010428318776485. doi: 10.1177/1010428318776485.
6
Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10981-E10990. doi: 10.1073/pnas.1712514114. Epub 2017 Dec 4.
7
The Immune Landscape in Women Cancers.
Cancer Treat Res. 2020;180:215-249. doi: 10.1007/978-3-030-38862-1_8.
8
Myeloid-derived suppressor cells in ovarian cancer: friend or foe?
Cent Eur J Immunol. 2017;42(4):383-389. doi: 10.5114/ceji.2017.72823. Epub 2017 Dec 30.
9
Ovarian cancer and the immune system - The role of targeted therapies.
Gynecol Oncol. 2016 Aug;142(2):349-56. doi: 10.1016/j.ygyno.2016.05.007. Epub 2016 May 23.
10
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
Cancer Res. 2006 Jul 1;66(13):6807-15. doi: 10.1158/0008-5472.CAN-05-3755.
引用本文的文献
1
High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.
Turk J Obstet Gynecol. 2022 Sep 23;19(3):246-256. doi: 10.4274/tjod.galenos.2022.59558.
2
Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer.
NPJ Genom Med. 2022 Apr 28;7(1):30. doi: 10.1038/s41525-022-00300-5.
3
Tumor Immune Microenvironment Related Gene-Based Model to Predict Prognosis and Response to Compounds in Ovarian Cancer.
Front Oncol. 2021 Dec 13;11:807410. doi: 10.3389/fonc.2021.807410. eCollection 2021.
4
Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer.
Cancers (Basel). 2021 Nov 24;13(23):5899. doi: 10.3390/cancers13235899.
5
Predicting Panel of Metabolism and Immune-Related Genes for the Prognosis of Human Ovarian Cancer.
Front Cell Dev Biol. 2021 Jul 12;9:690542. doi: 10.3389/fcell.2021.690542. eCollection 2021.
6
Development and validation of an immune prognostic signature for ovarian carcinoma.
Cancer Rep (Hoboken). 2020 Aug;3(4):e1166. doi: 10.1002/cnr2.1166. Epub 2019 Feb 19.
7
Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Front Immunol. 2019 Jun 4;10:1273. doi: 10.3389/fimmu.2019.01273. eCollection 2019.
8
Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells.
PLoS One. 2018 Jun 21;13(6):e0197404. doi: 10.1371/journal.pone.0197404. eCollection 2018.
本文引用的文献
1
Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer.
Oncotarget. 2016 Sep 20;7(38):61336-61354. doi: 10.18632/oncotarget.11038.
2
Ovarian cancer and the immune system - The role of targeted therapies.
Gynecol Oncol. 2016 Aug;142(2):349-56. doi: 10.1016/j.ygyno.2016.05.007. Epub 2016 May 23.
3
Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course.
Oncoimmunology. 2015 Dec 21;5(4):e1111505. doi: 10.1080/2162402X.2015.1111505. eCollection 2016 Apr.
4
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.
Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307.
5
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
Cancer Cell. 2015 Dec 14;28(6):690-714. doi: 10.1016/j.ccell.2015.10.012.
6
Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma.
Contemp Oncol (Pozn). 2015;19(4):290-9. doi: 10.5114/wo.2015.54388. Epub 2015 Sep 18.
7
FoxP3+ regulatory T cells in peripheral blood of patients with epithelial ovarian cancer.
Iran J Immunol. 2014 Jun;11(2):105-12.
8
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.
J Transl Med. 2013 Jun 18;11:149. doi: 10.1186/1479-5876-11-149.
9
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression.
J Cell Mol Med. 2010 Dec;14(12):2748-59. doi: 10.1111/j.1582-4934.2009.00911.x.
10
Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments.
Immunol Rev. 2009 Jul;230(1):144-59. doi: 10.1111/j.1600-065X.2009.00787.x.
Zotero 插件